Vivos Therapeutics Aims for Cash Flow Positive Operations by 2026 with Scaling Sales Operations

Vivos Therapeutics (NASDAQ:VVOS) plans to achieve cash flow positive operations by the end of 2026 as it scales its sales operations teams, with the potential to collect over $500,000 monthly. The company's CEO highlighted 2025 as a pivotal year, confirming strong patient demand for its Vivos method.

By SA Transcript Insights Editor, SA News Editor · Seeking Alpha · April 15, 2026, 22:42 UTC

Tickers: $VVOS

Topics: Company Performance Management Commentary Q4 2025 Earnings Vivos Therapeutics

Read the full article at Seeking Alpha

More World news

Sprott Physical Gold Trust USD Reports Q3 Net Income of $508.82 Million Seeking Alpha · November 12, 2026, 18:07 UTC
NYSE Gains $500 Billion in Market Capitalization via Nine Major Listing Transfers PR Newswire · November 12, 2026, 18:05 UTC
PenFed Foundation Grants $25,000 to Northern Virginia Vietnam Veterans Foundation PR Newswire · November 12, 2026, 18:06 UTC
Allstate Announces Quarterly Dividend of $1.08 Per Share Seeking Alpha · November 12, 2026, 18:01 UTC
Pinnacle Bankshares Increases Quarterly Dividend to $0.35 Per Share Seeking Alpha · November 12, 2026, 18:02 UTC
Avidbank Reports Third Quarter 2026 Earnings Growth Driven by Core Deposits and C&I Lending Motley Fool · November 12, 2026, 18:00 UTC
Equinor Raises Production Guidance and Establishes Share Buyback Framework Motley Fool · November 12, 2026, 18:00 UTC
Flex Announces Strategic Spin-off of Cloud and Power Infrastructure Segment into Axiom Motley Fool · November 12, 2026, 18:00 UTC
Extreme Networks Raises Fiscal 2027 Revenue Guidance Amid Strong SaaS Growth and Large Enterprise Bookings Motley Fool · November 12, 2026, 18:00 UTC
Federal Reserve to Designate October 2027 Meeting as Nonvoting Strategic Session CNBC · November 12, 2026, 17:48 UTC